List of Excipients in Branded Drug OLPRUVA

« Back to Dashboard

OLPRUVA Excipient Strategy and Commercial Opportunities in Urea Cycle Disorders

Last updated: October 8, 2026

OLPRUVA is an oral powder for suspension containing sodium phenylbutyrate for chronic management of urea cycle disorders (UCDs). Its commercial differentiation is primarily formulation-based: pediatric acceptability, dosing flexibility, simplified administration, and potentially better adherence than sodium phenylbutyrate tablets or liquid products. The main formulation constraints are sodium burden, strong taste and odor, powder dispersion, dose volume, and long-term use in children.

What is OLPRUVA and how does its formulation work?

OLPRUVA contains sodium phenylbutyrate, a nitrogen-scavenging agent that is metabolized to phenylacetate. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted in urine and removes nitrogen from the body.

The FDA approved OLPRUVA in December 2022 for patients aged two years and older with UCDs who cannot be adequately managed with dietary protein restriction and supplementation alone. The product is supplied as oral powder for suspension in single-dose packets. The powder is mixed before administration rather than swallowed as a tablet or measured from a bottle.[1]

Key product characteristics

Attribute	OLPRUVA
Active ingredient	Sodium phenylbutyrate
Dosage form	Oral powder for suspension
Primary indication	Chronic management of UCDs
Patient population	Adults and pediatric patients aged 2 years and older
Administration	Packet contents mixed with liquid before oral administration
Therapeutic category	Nitrogen scavenger
Major clinical constraints	Sodium load, taste, odor, gastrointestinal tolerability, adherence
Main alternatives	BUPHENYL, sodium phenylbutyrate generics, RAVICTI
Regulatory pathway	FDA 505(b)(2)-type approval framework for a previously approved active ingredient and new dosage form

The formulation does not create a new pharmacologic mechanism. Its value is in delivery, dosing convenience, and patient usability.

What excipients are used in OLPRUVA?

FDA labeling identifies maltodextrin and colloidal silicon dioxide as inactive ingredients in OLPRUVA.[1] These excipients support powder manufacture and handling but do not remove the principal clinical limitations of sodium phenylbutyrate.

Excipient	Likely formulation function	Commercial relevance
Maltodextrin	Carrier, bulking agent, powder-processing aid, dispersion support	Helps create a manageable unit-dose powder and may reduce segregation during filling
Colloidal silicon dioxide	Glidant and anticaking agent	Improves flow, packet filling, and powder handling

The limited excipient system is commercially relevant. A short, conventional excipient list can simplify regulatory review, reduce raw-material complexity, and support manufacturing scale-up. It also limits opportunities to solve taste, odor, and sodium-related problems through the current formulation.

What is not solved by the current excipient system?

Maltodextrin and colloidal silicon dioxide do not materially change the sodium content of the drug product. Sodium phenylbutyrate contains a high sodium burden, and the FDA label warns that this is clinically relevant, especially for patients with congestive heart failure, renal impairment, or other conditions in which sodium intake is restricted.[1]

The excipients also do not provide a complete taste-masking solution. Phenylbutyrate products are difficult to administer over long periods because of unpleasant taste and odor. A powder that must be dispersed before use may be more acceptable than tablets for some children, but the active ingredient remains the primary organoleptic challenge.

How should an excipient strategy for OLPRUVA evolve?

The most attractive strategy is to maintain a low-complexity powder platform while adding targeted technologies for palatability, dose flexibility, and administration.

Taste and odor masking

Potential approaches include:

• Polymer coating of sodium phenylbutyrate particles.
• Ion-exchange resin complexes.
• Lipid or cyclodextrin-based inclusion systems.
• Flavor systems compatible with the product’s mixing instructions.
• Microencapsulation with controlled release during swallowing.
• Multiparticulate granules that reduce immediate contact with taste receptors.

A taste-masking system must preserve rapid and predictable release after administration. It also must avoid increasing packet size, dose volume, or preparation complexity. For pediatric UCD treatment, an excipient technology that requires multiple mixing steps could reduce the adherence benefit of the product.

Flavor selection should account for the product’s use in infants, young children, and patients with feeding difficulties. Fruit flavors may improve acceptance, but flavor alone is unlikely to overcome the strong taste and odor of sodium phenylbutyrate. A physical barrier is more defensible as a formulation strategy than a flavor-only approach.

Sodium reduction

A true low-sodium version would require a different salt or chemical form, not a conventional excipient change. Potential development routes include:

• Sodium-free phenylbutyrate formulations using an alternative counterion.
• Phenylbutyric acid formulations with improved palatability and dose control.
• Prodrug approaches.
• Higher-potency formulations that reduce total mass administered.
• Modified-release systems that lower peak local exposure in the mouth.

These approaches may create a stronger product distinction but would increase development, toxicology, CMC, and regulatory requirements. A counterion change could also affect absorption, stability, bioavailability, and the regulatory relationship to existing sodium phenylbutyrate products.

Dispersion and suspension control

For a product used chronically in children, the suspension should wet quickly, disperse uniformly, and remain easy to administer. Potential excipient improvements include:

• Wetting agents to reduce floating and clumping.
• Suspending agents to improve uniformity during the administration window.
• Buffer systems to stabilize the product after mixing.
• Controlled particle-size distribution.
• Unit-dose packaging designed to minimize powder retention.

Any suspension aid must be evaluated for gastrointestinal tolerability and compatibility with the permitted mixing vehicle. The commercial target should be a short preparation time with minimal sedimentation, not a technically complex reconstitution procedure.

What formulations are protected by OLPRUVA’s intellectual property?

The commercial protection for OLPRUVA is likely to depend more on formulation, dosage-form, manufacturing, and regulatory exclusivity than on composition-of-matter protection for sodium phenylbutyrate. Sodium phenylbutyrate was previously marketed, including as BUPHENYL, which limits the scope for new-molecule patent protection.

Potentially protectable elements include:

1. Unit-dose oral powder packets.
2. Specific particle-size distributions.
3. Powder blends containing sodium phenylbutyrate, maltodextrin, and colloidal silicon dioxide.
4. Mixing procedures and administration vehicles.
5. Taste-masking systems.
6. Pediatric dosing regimens.
7. Manufacturing processes that improve content uniformity.
8. Packaging that protects powder flow and stability.
9. Formulations that reduce odor or improve suspension characteristics.

The FDA label and public Orange Book materials should be used to distinguish approved product information from patent claims. FDA labeling confirms the dosage form and inactive ingredients but does not establish that every formulation element is patent-protected.[1,2]

When does OLPRUVA lose exclusivity?

OLPRUVA’s active ingredient does not have new-molecule exclusivity because sodium phenylbutyrate predates the product. The relevant commercial barriers are likely to include FDA regulatory exclusivity, orphan-drug considerations, listed patents if any, formulation know-how, and market access.

Regulatory exclusivity

The approval of a new dosage form or formulation of an existing active ingredient may support three-year exclusivity if the approval relied on new clinical investigations conducted or sponsored by the applicant and essential to approval. The precise scope and end date must be confirmed from FDA exclusivity records and the Orange Book.[2,3]

Orphan-drug exclusivity may be relevant because UCDs are rare diseases. The practical value of orphan exclusivity depends on the approved indication, the identity of the drug, and whether another product is considered the same drug for the same disease. Prior approval of sodium phenylbutyrate products can complicate the competitive effect of orphan exclusivity.

Patent expiration

No composition-of-matter patent for sodium phenylbutyrate can be expected to block generic development. Any meaningful patent barrier would more likely arise from later-filed claims covering the OLPRUVA dosage form, excipient system, manufacturing process, or use.

A generic manufacturer could pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence, or it could use a 505(b)(2) pathway for a materially different formulation. Formulation patents could delay or narrow competition, but they would not necessarily prevent all alternative sodium phenylbutyrate products.

What is the Orange Book status of OLPRUVA?

OLPRUVA should be evaluated through three Orange Book questions:

• Is the product listed as an approved drug product?
• Are patents listed against the product?
• Is regulatory exclusivity shown, and what is its expiration date?

The Orange Book is the controlling public source for FDA-listed patents and exclusivity tied to approved drug products.[2] A patent not listed in the Orange Book may still be asserted in litigation, but it would not automatically trigger the same ANDA certification framework as a listed patent.

Because OLPRUVA uses an existing active ingredient in a new oral powder presentation, the principal Orange Book risk is likely to come from listed formulation or method-of-use patents rather than active-ingredient patents.

What generic entry risks exist for OLPRUVA?

Generic entry risk is moderate to high over the long term because sodium phenylbutyrate is an established active ingredient and multiple alternative products exist.

Generic pathway

A competitor could develop:

• An oral powder equivalent.
• A tablet or capsule product.
• An oral liquid.
• A 505(b)(2) product with a different excipient or delivery system.
• A lower-cost product for adult patients who do not require pediatric powder administration.

The most direct challenge would target pharmaceutical equivalence, dose delivery, and bioequivalence. The key technical issues would include powder homogeneity, packet strength, dissolution, active-ingredient stability, and administration instructions.

Paragraph IV challenges

A Paragraph IV certification could arise if a generic applicant believes that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The commercial significance depends on whether OLPRUVA has listed patents covering the specific powder formulation or use.

If no blocking formulation patents are listed, the regulatory barrier may be limited to exclusivity and FDA review. If multiple formulation patents are listed, the first qualified Paragraph IV filer could obtain 180-day exclusivity, subject to the statutory conditions governing that exclusivity.[3]

How does OLPRUVA compare with BUPHENYL and RAVICTI?

Product	Active ingredient	Dosage form	Main differentiation	Main weakness
OLPRUVA	Sodium phenylbutyrate	Oral powder for suspension	Unit-dose pediatric-oriented administration and dosing flexibility	Sodium burden, taste, packet preparation
BUPHENYL	Sodium phenylbutyrate	Tablets and oral powder	Established product and physician familiarity	Palatability, sodium load, tablet burden
RAVICTI	Glycerol phenylbutyrate	Oral liquid	Lower dosing frequency and different organoleptic profile	Cost, liquid administration, access restrictions
Generic sodium phenylbutyrate	Sodium phenylbutyrate	Varies	Lower acquisition cost	Variable usability and formulation quality

RAVICTI is the most important branded comparator because it uses glycerol phenylbutyrate, a different prodrug designed to provide a liquid nitrogen-scavenging therapy. OLPRUVA competes by offering a solid-dose, unit-dose presentation rather than by reducing sodium exposure.

For pediatric patients who cannot swallow tablets, OLPRUVA may be positioned against BUPHENYL powder and RAVICTI. For cost-sensitive payers, generic sodium phenylbutyrate products create pressure. For patients requiring lower sodium exposure or less frequent dosing, RAVICTI may have a stronger clinical and commercial position.

What commercial opportunities exist for OLPRUVA excipients?

Pediatric adherence

The largest opportunity is not a new excipient alone. It is a complete adherence platform combining:

• Better taste masking.
• Smaller preparation burden.
• Clear dose graduations.
• Unit-dose packaging.
• Administration with permitted foods or liquids.
• Caregiver instructions that reduce preparation errors.

A formulation that improves acceptance could support premium pricing if payers and prescribers recognize lower treatment discontinuation and better dosing reliability.

New dosage strengths

Additional packet strengths could improve dose matching across body weights and reduce partial-packet use. This may lower waste and simplify titration. Strength expansion also creates lifecycle-management opportunities if supported by pharmacokinetic and usability data.

Ready-to-use formats

A ready-to-use oral suspension or dispersible granule product could compete directly with liquid formulations. The commercial tradeoff is higher packaging cost, greater stability risk, and potentially higher shipping expense.

Compounding and specialty pharmacy channels

A stable, standardized powder may be attractive to specialty pharmacies and hospital systems because it reduces reliance on extemporaneous compounding. Institutional purchasing could expand if the product demonstrates consistent dosing, low preparation error rates, and reliable supply.

What manufacturing and IP barriers matter most?

The main manufacturing barriers are technical rather than chemical:

• Achieving content uniformity across low- and high-strength packets.
• Preventing segregation between sodium phenylbutyrate and excipients.
• Controlling moisture uptake.
• Maintaining powder flow during high-speed filling.
• Preserving stability during storage and shipment.
• Validating dose delivery after mixing.
• Managing odor release during manufacturing and administration.

A differentiated manufacturing process could be valuable even if it does not create a broad patent barrier. Know-how around blending, particle engineering, coating, packet filling, and stability may be difficult for a generic competitor to replicate quickly.

What patent litigation or settlement risks affect OLPRUVA?

Potential litigation would most likely involve formulation patents, manufacturing claims, or method-of-use claims rather than the sodium phenylbutyrate molecule. A generic applicant could challenge listed patents through a Paragraph IV certification, while the sponsor could assert infringement after receiving the required notice.

Settlement terms could include delayed entry, a license to a specific formulation, or restrictions tied to dosage form and indication. No commercial forecast should assume delayed generic entry without verified Orange Book listings, litigation filings, or a disclosed settlement.

Key Takeaways

• OLPRUVA’s commercial value rests on dosage-form convenience rather than new pharmacology.
• Maltodextrin and colloidal silicon dioxide support powder processing but do not solve sodium burden or the core taste problem.
• The strongest lifecycle opportunity is a taste-masked, low-preparation pediatric formulation.
• Sodium reduction would require a different chemical form or prodrug strategy, not a conventional excipient adjustment.
• Generic risk is structurally significant because sodium phenylbutyrate is an established active ingredient.
• Formulation, manufacturing, and method-of-use patents are more commercially relevant than composition-of-matter patents.
• RAVICTI is the principal branded comparator; generic sodium phenylbutyrate is the main price competitor.
• Unit-dose packet technology, additional strengths, and ready-to-use presentations are the clearest commercial expansion opportunities.

FAQs

Can OLPRUVA be reformulated without changing its FDA approval pathway?

Minor excipient changes may be possible through post-approval supplements, but material changes to taste masking, release, counterion, or bioavailability could require additional clinical and CMC support.

Does maltodextrin reduce the sodium content of OLPRUVA?

No. Maltodextrin acts mainly as a carrier or bulking agent. It does not change the sodium contribution from sodium phenylbutyrate.

Is OLPRUVA a biologic subject to biosimilar competition?

No. OLPRUVA is a small-molecule drug product. Biosimilar regulation does not apply; competition would arise through generic or 505(b)(2) pathways.

Could a competitor launch a lower-sodium version of OLPRUVA?

Yes, but a lower-sodium product would likely require a new chemical form, prodrug, or higher-potency delivery system and would face additional regulatory and clinical requirements.

What is the most valuable excipient innovation for OLPRUVA?

A robust taste- and odor-masking system that preserves rapid release, reduces preparation steps, and remains acceptable for chronic pediatric use would have the clearest commercial value.

References

1. U.S. Food and Drug Administration. (2022). OLPRUVA (sodium phenylbutyrate) oral powder for suspension: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certification requirements.